Talphera

Talphera EPS Growth

The EPS Growth of Talphera (TLPH) as of Nov 4, 2026 is 32.02 %. In the previous year, EPS Growth was 50.51 % — a change of -36.62% (lower).

EPS Growth

32.02 %

YoY

-36.62%

Last updated:

EPS Growth of Talphera is 2025 32.02 % . EPS Growth of Talphera was 2024 50.51 % . It decreases by -36.62% lower compared to the previous year.

The Talphera EPS Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS Growth
Date
EPS Growth
Jan 1, 2018
34.69 USD
Jan 1, 2019
-0.22 USD
Jan 1, 2020
34.61 USD
Jan 1, 2021
37.17 USD
Jan 1, 2022
203.58 USD
Jan 1, 2023
-117.59 USD
Jan 1, 2024
50.51 USD
Jan 1, 2025
32.02 USD
The Talphera EPS Growth history
YEAREPS GrowthYoY
32.02 %-36.62%
50.51 %-142.96%
-117.59 %-157.76%
203.58 %+447.65%
37.17 %+7.42%
34.61 %-15,958.84%
-0.22 %-100.63%
34.69 %-570.59%
-7.37 %-90.02%
-73.89 %-361.52%
28.25 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Talphera Stock analysis

What does Talphera do? Talphera Inc develops and commercializes therapies for medically supervised settings, focusing on nafamostat-based products. The company's Niyad targets regional anticoagulants for dialysis circuits in acute kidney injury and chronic kidney disease patients. LTX-608 is an intravenous formulation for potential treatment of viral infections, ARDS, DIC, and acute pancreatitis. Pre-filled syringes Fedsyra and PFS-02 are also under development. The firm sells these products to hospitals, dialysis centers, and medical facilities requiring specialized therapies in controlled environments. Niyad is designed for use during continuous renal replacement therapy and hemodialysis procedures, primarily targeting healthcare providers in hospital settings and dialysis centers. LTX-608 aims to address viral and inflammatory conditions, with potential buyers including hospitals treating respiratory and coagulation disorders. The pre-filled syringes Fedsyra and PFS-02 serve as delivery systems for these therapies, appealing to medical institutions needing efficient administration solutions. The company's revenue streams come from the sale of Niyad, LTX-608, Fedsyra, and PFS-02 to healthcare providers. Hospitals and dialysis centers are key buyers for Niyad, while LTX-608 targets hospitals managing viral outbreaks and severe inflammatory conditions. Fedsyra and PFS-02 are sold as complementary products to support the delivery of nafamostat therapies, with demand driven by the need for specialized medical treatments in supervised care settings. Talphera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Talphera stock

EPS Growth of Talphera is 32.02 % in 2025.

On Eulerpool you can find the complete historical development of EPS Growth Talphera since 2006 – with annual values, charts, and detailed analysis.

EPS growth measures the percentage change in earnings per share. It accounts for both profit changes and share count changes.

To evaluate EPS Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS Growth.

EPS Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS Growth's Talphera historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Growth — Talphera

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — Talphera